Use of sofosbuvir-based regimens in the treatment of adolescents and children with chronic hepatitis C
10.3760/cma.j.cn501113-20190606-00199
- VernacularTitle:基于索磷布韦的方案在未成年慢性丙型肝炎患者中的应用
- Author:
Shan HE
1
;
Xiaoyun WANG
;
Qunying HAN
;
Zhengwen LIU
Author Information
1. 西安交通大学第一附属医院感染科 710061
- Keywords:
Hepatitis C;
Sofosbuvir;
Direct-acting antivirals;
Adolescents;
Children
- From:
Chinese Journal of Hepatology
2021;29(1):83-86
- CountryChina
- Language:Chinese
-
Abstract:
Sofosbuvir has ushered in a new era of hepatitis C treatment with its strong inhibition on the replication of hepatitis C virus, favorable safety profile and less interactions with other drugs. Sofosbuvir-based regimens have been included as the first-line therapies for the treatment of adults with chronic hepatitis C (CHC) in international guidelines. Available clinical trial data show that sofosbuvir with ribavirin and ledipasvir/sofosbuvir are highly efficacious and safe in CHC patients aged 3-17 years old; therefore, they can meet the unmet medical needs of adolescents and children with CHC in China. Furthermore, the pan-genotypic sofosbuvir/velpatasvir is being investigated in adolescents and children with CHC, which is expected to make the treatment in such patients more convenient upon approval.
